Retatrutide Side Effects Chart: Frequency by Dose
This reference chart presents retatrutide side effect data from the Phase 2 clinical trial (Jastreboff et al., NEJM 2023), organized by dose level to help patients and providers understand how side effects scale with dosing. Understanding these patterns supports informed decision-making about dose escalation.
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Side effect rates are approximate and based on Phase 2 data with limited sample sizes. Individual experiences vary. Report all side effects to your healthcare provider.
GI Side Effects by Dose
| Side Effect | Placebo | 1mg | 4mg | 8mg | 12mg |
|---|---|---|---|---|---|
| Nausea | ~6% | ~12% | ~18% | ~24% | ~26% |
| Diarrhea | ~5% | ~8% | ~15% | ~20% | ~22% |
| Vomiting | ~2% | ~4% | ~8% | ~12% | ~15% |
| Constipation | ~3% | ~6% | ~8% | ~10% | ~12% |
| Decreased appetite | ~2% | ~8% | ~15% | ~18% | ~20% |
| Abdominal pain | ~3% | ~5% | ~7% | ~8% | ~10% |
Approximate rates from Jastreboff et al., NEJM 2023. Individual results vary.
Retatrutide-Specific Side Effects
| Side Effect | Likely Mechanism | Frequency | Notes |
|---|---|---|---|
| Dysesthesia (tingling/burning) | Glucagon receptor on nerves | Higher at 8-12mg | Usually transient; unique to retatrutide |
| Increased heart rate | GLP-1 class effect | Dose-dependent | 2-4 bpm average increase |
| Injection site reactions | Local response | ~5-8% | Usually mild; rotate sites |
Side Effect Timeline
Most side effects follow a predictable pattern: they appear or worsen within 24-72 hours of each dose escalation, peak during weeks 1-2 of the new dose, improve by weeks 3-4 as the body adapts, and resolve or become minimal at the maintenance dose. Patients who understand this pattern are better equipped to tolerate the titration phase.
Comparison to Other GLP-1 Medications
| Side Effect | Semaglutide 2.4mg | Tirzepatide 15mg | Retatrutide 12mg |
|---|---|---|---|
| Nausea | ~44% | ~31% | ~26% |
| Diarrhea | ~30% | ~23% | ~22% |
| Vomiting | ~24% | ~12% | ~15% |
| Discontinuation rate | ~7% | ~5-7% | ~5-6% |
Cross-trial comparisons are approximate; direct head-to-head data not available.
Serious Side Effects (Rare)
- Pancreatitis: Rare but serious; stop medication and seek care for severe abdominal pain radiating to back
- Gallbladder events: Cholecystitis and cholelithiasis may occur with rapid weight loss
- Thyroid C-cell tumors: Boxed warning based on rodent data; no confirmed human cases
- Hypoglycemia: Rare alone; risk increases with insulin or sulfonylureas
- Acute kidney injury: From dehydration due to GI side effects; maintain hydration
GLP-1 Treatment With Side Effect Support
Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with medical teams who actively manage side effects. Learn how Trimi works.
Frequently Asked Questions
Does retatrutide have more side effects than semaglutide?
Surprisingly, Phase 2 data suggests comparable or lower GI side effect rates. Retatrutide does have unique effects like dysesthesia that other GLP-1s lack, but overall tolerability appears similar or better.
Do side effects get worse at higher doses?
Side effect rates increase modestly with dose, but the body adapts at each level. The side effects at 12mg are not dramatically worse than at 8mg because patients have acclimated through gradual titration.
What percentage of patients stop due to side effects?
Approximately 5-6% of Phase 2 trial participants discontinued due to adverse events, which is comparable to or lower than other GLP-1 medications.
Are Phase 3 side effects expected to be different?
Phase 3 trials with larger populations may identify rare side effects not captured in Phase 2. Overall rates for common side effects are expected to be similar.
More on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).